Sona Nanotech Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. has announced that its innovative gold nanorod-based targeted hyperthermia therapy (THT) has shown promising results in treating melanoma in preclinical trials, following success with triple negative breast cancer. The therapy, possibly enhanced by a second dose of near-infrared light, not only performed well alone but also demonstrated a significant synergistic effect when combined with standard immunotherapy. These findings bolster the company’s plan to advance towards human clinical trials for treating solid cancers like late-stage melanoma.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
